| |  Online-Ressource |
|---|
| Verfasst von: | Röder, Falk [VerfasserIn]  |
|---|
| | Timke, Carmen [VerfasserIn] |
|---|
| | Saleh-Ebrahimi, Ladan [VerfasserIn] |
|---|
| | Schneider, Lutz [VerfasserIn] |
|---|
| | Hackert, Thilo [VerfasserIn] |
|---|
| | Hartwig, Werner [VerfasserIn] |
|---|
| | Kopp-Schneider, Annette [VerfasserIn] |
|---|
| | Hensley, Frank W. [VerfasserIn] |
|---|
| | Büchler, Markus W. [VerfasserIn] |
|---|
| | Debus, Jürgen [VerfasserIn] |
|---|
| | Huber, Peter E. [VerfasserIn] |
|---|
| | Werner, Jens [VerfasserIn] |
|---|
| Titel: | Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5 × 5 gy) and intraoperative radiation therapy (15 gy) in patients with primarily resectable pancreatic cancer - NEOPANC |
|---|
| Verf.angabe: | Falk Roeder, Carmen Timke, Ladan Saleh-Ebrahimi, Lutz Schneider, Thilo Hackert, Werner Hartwig, Annette Kopp-Schneider, Frank W. Hensley, Markus W. Buechler, Juergen Debus, Peter E. Huber and Jens Werner |
|---|
| E-Jahr: | 2012 |
|---|
| Jahr: | 23 March 2012 |
|---|
| Fussnoten: | Gesehen am 14.08.2018 |
|---|
| Titel Quelle: | Enthalten in: BMC cancer |
|---|
| Ort Quelle: | London : BioMed Central, 2001 |
|---|
| Jahr Quelle: | 2012 |
|---|
| Band/Heft Quelle: | 12(2012) Artikel-Nummer 112, 8 Seiten |
|---|
| ISSN Quelle: | 1471-2407 |
|---|
| Abstract: | The current standard treatment, at least in Europe, for patients with primarily resectable tumors, consists of surgery followed by adjuvant chemotherapy. But even in this prognostic favourable group, long term survival is disappointing because of high local and distant failure rates. Postoperative chemoradiation has shown improved local control and overalls survival compared to surgery alone but the value of additional radiation has been questioned in case of adjuvant chemotherapy. However, there remains a strong rationale for the addition of radiation therapy considering the high rates of microscopically incomplete resections after surgery. As postoperative administration of radiation therapy has some general disadvantages, neoadjuvant and intraoperative approaches theoretically offer benefits in terms of dose escalation, reduction of toxicity and patients comfort especially if hypofractionated regimens with highly conformal techniques like intensity-modulated radiation therapy are considered. |
|---|
| DOI: | doi:10.1186/1471-2407-12-112 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Kostenfrei: Volltext ; Verlag: http://dx.doi.org/10.1186/1471-2407-12-112 |
|---|
| | Kostenfrei: Volltext: https://doi.org/10.1186/1471-2407-12-112 |
|---|
| | DOI: https://doi.org/10.1186/1471-2407-12-112 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1578852889 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5 × 5 gy) and intraoperative radiation therapy (15 gy) in patients with primarily resectable pancreatic cancer - NEOPANC / Röder, Falk [VerfasserIn]; 23 March 2012 (Online-Ressource)
